Archives202520242023202220212020201920182017201620152014201320122011 December 22, 2022End of Year Update Read More November 18, 2022Avion confirms its continued support to the Lupuzor™ clinical program in Lupus whilst exploring broader collaboration opportunities Read More September 30, 2022Lupuzor™ Update Read More September 30, 2022INTERIM RESULTS for the six months ended 30 June 2022 Read More September 15, 2022Written response received from the FDA Read More September 07, 2022Exercise of Options | L1 Capital Read More August 31, 2022FDA response for Type C Meeting – update Read More August 31, 2022Exercise of Options Read More August 24, 2022Exercise of Options Read More August 18, 2022Lanstead Capital TR1 Read More May 04, 2022UPDATE on LUPUZOR™ – POSITIVE PROGRESS to PHASE 3 with AVION Read More April 13, 2022UPDATE on P140 (LUPUZOR™) clinical progress. Data confirms positive readout from P140 PK study. Read More 1…45678…16
November 18, 2022Avion confirms its continued support to the Lupuzor™ clinical program in Lupus whilst exploring broader collaboration opportunities Read More
April 13, 2022UPDATE on P140 (LUPUZOR™) clinical progress. Data confirms positive readout from P140 PK study. Read More
